Payment overview · 2025
General Payments
$1,606.20
97 reported records · 26 companies
Healthcare provider profile · identity verified
Jeffrey D. Floyd, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OKLAHOMA CITY, OK · NPI 1629002761
Verified facts
What the public records show
CMS Open Payments records show Jeffrey D. Floyd, M.D. received $1,606.20 in general payments during 2025 across 97 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $227.83 | 14.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.26 | 11.0% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.59 | 10.1% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.11 | 9.2% | 6 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $121.93 | 7.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.22 | 5.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $86.97 | 5.4% | 5 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $79.11 | 4.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.39 | 4.3% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.91 | 4.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.73 | 3.9% | 4 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $44.22 | 2.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.41 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.00 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.58 | 1.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.07 | 1.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.29 | 1.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.62 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.15 | 1.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.14 | 1.0% | 1 | 2025 |
| Vertical Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.07 | 1.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.41 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.06 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.75 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.54 | 0.9% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $13.84 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,606.20 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $206.67 | 10 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $121.93 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $121.93 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $121.93 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $116.19 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.32 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $93.22 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.22 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.23 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $86.97 | 5 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $79.11 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.37 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.68 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.39 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.39 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.07 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.61 | 4 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $44.22 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.05 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.58 | 3 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Relexxii Normalized: relexxii |
Drug | Vertical Pharmaceuticals, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 271 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 68 |
| Celecoxib | Celecoxib | 183 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 54 |
| Metformin Hcl Er | Metformin Hcl | 153 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 45 |
| Alprazolam | Alprazolam | 136 | 29 |
| Trazodone Hcl | Trazodone Hcl | 133 | 46 |
| Gabapentin | Gabapentin | 130 | 50 |
| Ozempic | Semaglutide | 127 | 29 |
| Montelukast Sodium | Montelukast Sodium | 122 | 37 |
| Meloxicam | Meloxicam | 120 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 28 |
| Lisinopril | Lisinopril | 104 | 31 |
| Memantine Hcl | Memantine Hcl | 102 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 20 |
| Sertraline Hcl | Sertraline Hcl | 97 | 28 |
| Baclofen | Baclofen | 96 | 27 |
| Valsartan | Valsartan | 96 | 29 |
| Losartan Potassium | Losartan Potassium | 85 | 26 |
| Tramadol Hcl | Tramadol Hcl | 84 | 18 |
| Eliquis | Apixaban | 83 | 19 |
| Allopurinol | Allopurinol | 81 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 24 |
| Jardiance | Empagliflozin | 75 | 19 |
| Omeprazole | Omeprazole | 70 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 22 |
| Clonazepam | Clonazepam | 55 | 12 |
| Potassium Chloride | Potassium Chloride | 54 | 20 |
| Synthroid | Levothyroxine Sodium | 52 | 13 |
| Metformin Hcl | Metformin Hcl | 51 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 17 |
| Pregabalin | Pregabalin | 48 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 20 |
| Furosemide | Furosemide | 43 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 17 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Cefdinir | Cefdinir | 39 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 12 |
| Spironolactone | Spironolactone | 38 | 15 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 11 |
| Diazepam | Diazepam | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 11 |
| Myrbetriq | Mirabegron | 30 | 13 |
| Carvedilol | Carvedilol | 29 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 12 |
| Fluconazole | Fluconazole | 23 | 13 |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Afrezza | Insulin Regular, Human | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 11 |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Clarithromycin Er | Clarithromycin | 15 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Risperidone | Risperidone | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,606.20 · 97 records | Teva Pharmaceuticals USA, Inc. | AIRSUPRA, AJOVY, AREXVY, AUSTEDO XR, CAPVAXIVE, FARXIGA, FREESTYLE LIBRE 3, Flector, GARDASIL 9, GEMTESA, Heplisav-B, INSPIRE, JARDIANCE, Jornay PM, KISUNLA, Kerendia, Korlym, LEQVIO, Licart, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROQUAD, QULIPTA, REPATHA, Relexxii, Rybelsus, SHINGRIX, Sunosi, Symbravo, TONMYA, TRINTELLIX, Tirosint, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, WAKIX, Wegovy, XYOSTED, Xelstrym, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error